Transfer factor therapy in multiple sclerosis: a three-year prospective double-blind clinical trial

Area of Science:

• Immunology
• Neurology
• Cellular Biology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Investigating novel immunotherapies for MS is crucial for managing disease progression and improving patient outcomes.
• Transfer factor, derived from leukocytes, has been explored for its potential immunomodulatory effects.

Purpose of the Study:

• To evaluate the efficacy of transfer factor therapy in patients with multiple sclerosis.
• To determine the impact of transfer factor on clinical disability, daily living activities, and neurological function.
• To assess the effect of transfer factor on specific immune parameters, including gamma-interferon production and natural killer cell activity.

Main Methods:

• A randomized controlled trial involving 105 patients with MS.
• Patients were divided into three groups: placebo, transfer factor from random donors, and transfer factor from family members.
• Assessments included changes in disability, activities of daily living, evoked potentials, gamma-interferon production, and natural killer cell activity over 18 months.

Main Results:

• No significant differences were observed between the three treatment groups in terms of changes in disability, activities of daily living, or evoked potentials.
• Eighteen months of transfer factor therapy did not alter gamma-interferon production.
• Natural killer cell activities remained unchanged in all treatment groups.

Conclusions:

• Transfer factor therapy, using either random donor or family member-derived factors, demonstrated no clinical or immunological benefit in MS patients over an 18-month period.
• The study suggests that transfer factor is not an effective treatment for multiple sclerosis.
• Further research may be needed to explore other immunomodulatory strategies for MS management.